RT Journal Article
T1 Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life.
A1 Santos García, D
A1 De Deus Fonticoba, T
A1 Paz González, J M
A1 Cores Bartolomé, C
A1 Valdés Aymerich, L
A1 Muñoz Enríquez, J G
A1 Suárez, E
A1 Jesús, S
A1 Aguilar, M
A1 Pastor, P
A1 Planellas, L L
A1 Cosgaya, M
A1 García Caldentey, J
A1 Caballol, N
A1 Legarda, I
A1 Hernández Vara, J
A1 Cabo, I
A1 López Manzanares, L
A1 González Aramburu, I
A1 Ávila Rivera, M A
A1 Catalán, M J
A1 Nogueira, V
A1 Puente, V
A1 García Moreno, J M
A1 Borrué, C
A1 Solano Vila, B
A1 Álvarez Sauco, M
A1 Vela, L
A1 Escalante, S
A1 Cubo, E
A1 Carrillo Padilla, F
A1 Martínez Castrillo, J C
A1 Sánchez Alonso, P
A1 Alonso Losada, M G
A1 López Ariztegui, N
A1 Gastón, I
A1 Kulisevsky, J
A1 Blázquez Estrada, M
A1 Seijo, M
A1 Rúiz Martínez, J
A1 Valero, C
A1 Kurtis, M
A1 de Fábregues, O
A1 González Ardura, J
A1 Ordás, C
A1 López Díaz, L
A1 Mir, P
A1 Martinez-Martin, P
A1 Coppadis Study Group, 
AB In a degenerative disorder such as Parkinson's disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr's motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient's quality of life (QoL) with regard to a defined clinical stage. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0-20; B: NMSS = 21-40; C: NMSS = 41-70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (p  The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.
SN 2090-8083
YR 2021
FD 2021-05-13
LK https://hdl.handle.net/10668/27762
UL https://hdl.handle.net/10668/27762
LA en
DS RISalud
RD Apr 7, 2025